Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib

References

• Office for National Statistics Available from: www.ons.gov.ukAccessed September 30, 2013
   Google Scholar
• JanzenNKKimHLFiglinRABelldegrunASSurveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent diseaseUrol Clin North Am200330484385214680319
   PubMed Web of Science ®Google Scholar
• MotzerRJBanderNHNanusDMRenal-cell carcinomaN Engl J Med1996335128658758778606
   PubMed Web of Science ®Google Scholar
• FyfeGFisherRIRosenbergSASznolMParkinsonDRLouieACResults of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapyJ Clin Oncol19951336886967884429
   PubMed Web of Science ®Google Scholar
• YagodaAPetrylakDThompsonSCytotoxic chemotherapy for advanced renal cell carcinomaUrol Clin North Am19932023033218493752
   PubMed Web of Science ®Google Scholar
• FarmerBMagic bullet for cancerDaily Mail Online2006 Available at: http://www.dailymail.co.uk/health/article-398444/Magic-bullet-cancer.htmlAccessed September 30, 2013
   Google Scholar
• NaXWuGRyanCKSchoenSRDi’santagnesePAMessingEMOverproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomasJ Urol20031702 Pt 158859212853836
   PubMed Web of Science ®Google Scholar
• MendelDBLairdADXinXIn vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res20039132733712538485
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• Hu-loweDDZouHYGrazziniMLNonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3Clin Cancer Res200814227272728319010843
   PubMed Web of Science ®Google Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar
• RiniBIGrünwaldVFishmanMNAxitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic analyses from a randomized phase II studyJ Clin Oncol201230Suppl 18 Abstr 4503
   Google Scholar
• MotzerRJHutsonTECellaDPazopanib versus sunitinib in metastatic renal-cell carcinomaN Engl J Med2013369872273123964934
   PubMed Web of Science ®Google Scholar
• GoreMELarkinJMChallenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapiesBr J Cancer2011104339940621285971
   PubMed Web of Science ®Google Scholar
• HarshmanLCXieWBjarnasonGAConditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based studyLancet Oncol20121392793522877847
   PubMed Web of Science ®Google Scholar
• ThomasRGodwardSMakrisABloomfieldDMoodyAMWilliamsMGiving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozoleClin Oncol (R Coll Radiol)200416748549115490811
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical ExcellenceNICE recommends a new treatment for kidney cancer Available from: http://www.nice.org/newsroom/pressreleases/pazopanibForRenalCellCarcinoma.jspAccessed September 30, 2013
   Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• EscudierBJPortaCBonoPPatient preference between pazopanib and sunitinib: results of a randomized double-blind, placebo-controlled, crossover study in patients with metastatic renal cell carcinoma – PISCES study, NCT 01064310J Clin Oncol201230Suppl 18 Abstr CRA4502
   Google Scholar
• KumarRCrouthamelMCRomingerDHMyelosuppression and kinase selectivity of multikinase angiogenesis inhibitorsBr J Cancer2009101101717172319844230
   PubMed Web of Science ®Google Scholar
• NajjarYGElsonPWoodLSGarciaJADreicerRRiniBIAssociation of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinomaJ Clin Oncol201331Suppl 6 Abstr 406
   Web of Science ®Google Scholar
• DegnerLFSloanJADecision making during serious illness: what role do patients really want to play?J Clin Epidemiol19924599419501432023
   PubMed Web of Science ®Google Scholar
• FlynnKESmithMAPersonality and health care decision-making styleJ Gerontol B Psychol Sci Soc Sci2007625P261P26717906167
   PubMed Web of Science ®Google Scholar
• WilsonSRStrubPBuistASShared treatment decision making improves adherence and outcomes in poorly controlled asthmaAm J Respir Crit Care Med2010181656657720019345
   PubMed Web of Science ®Google Scholar
• MoumjidNCarrèreMOCharavelMBrémondAClinical issues in shared decision-making applied to breast cancerHealth Expect20036322222712940795
   PubMedGoogle Scholar
• El TurabiAAbelGARolandMLyratzopoulosGVariation in reported experience of involvement in cancer treatment decision making: evidence from the National Cancer Patient Experience SurveyBr J Cancer2013109378078723807170
   PubMed Web of Science ®Google Scholar
• VaishampayanUCabozantinib as a novel therapy for renal cell carcinomaCurr Oncol Rep2013152768223292795
   PubMed Web of Science ®Google Scholar
• BaileyAMcdermottDFImmune checkpoint inhibitors as novel targets for renal cell carcinoma therapeuticsCancer J201319434835223867517
   PubMed Web of Science ®Google Scholar
• MinasianLMMotzerRJGluckLMazumdarMVlamisVKrownSEInterferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-upJ Clin Oncol1993117136813758315435
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBTomczakPAxitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomized phase 3 trialLancet Oncol201314655256223598172
   PubMed Web of Science ®Google Scholar